America January 30, 2025
MaxCyte Buys SeQure Dx for Up to $7M
MaxCyte Inc., a leading cell therapy and gene editing company, announced Thursday that it has acquired SeQure Dx, a specialized…
America January 30, 2025
MaxCyte Inc., a leading cell therapy and gene editing company, announced Thursday that it has acquired SeQure Dx, a specialized…
By Rihem Akkouche